NIDDK Central Repository - Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial.

An official website of the United States government

NIDDK Central Repository

Publication Information

DOI

10.1161/CIRCULATIONAHA.110.000588

PubMed ID

21482964

Public Release Type

Journal

Publication Year

2011

Affiliation

Rhode Island Hospital, 110 Lockwood Street, Providence, RI 02903, USA. abostom@lifespan.org

Authors

Bostom AG, Carpenter MA, Cole E, Gravens-Mueller L, House AA, Hunsicker L, Jacques PF, Kew C, Kusek JW, Levey AS, McKenney JL, Pacheco-Silva A, Pesavento T, Pfeffer MA, Pirsch J, Selhub J, Smith S, Solomon S, Weir M

Studies

FAVORIT

Citation

Bostom AG, Carpenter MA, Kusek JW, Levey AS, Hunsicker L, Pfeffer MA, Selhub J, Jacques PF, Cole E, Gravens-Mueller L, House AA, Kew C, McKenney JL, Pacheco-Silva A, Pesavento T, Pirsch J, Smith S, Solomon S, Weir M. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation 2011 Apr 26;123(16):1763-70. Epub 2011 Apr 11.

Abstract

Kidney transplant recipients, like other patients with chronic kidney disease, experience excess risk of cardiovascular disease and elevated total homocysteine concentrations. Observational studies of patients with chronic kidney disease suggest increased homocysteine is a risk factor for cardiovascular disease. The impact of lowering total homocysteine levels in kidney transplant recipients is unknown.